Lineage Cell Therapeutics, Inc.
LCTX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.50 | -6.19 |
| FCF Yield | -0.91% | -2.68% | -4.79% | -6.67% |
| EV / EBITDA | -92.16 | -35.04 | -8.68 | -11.56 |
| Quality | ||||
| ROIC | -4.66% | -24.39% | -6.52% | -5.09% |
| Gross Margin | 0.00% | 98.59% | 97.60% | 94.63% |
| Cash Conversion Ratio | 0.12 | 0.18 | 1.18 | 1.94 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.23% | 1.22% | -6.92% | -13.55% |
| Free Cash Flow Growth | 36.88% | -13.65% | 27.19% | -17.76% |
| Safety | ||||
| Net Debt / EBITDA | 10.00 | 8.41 | 7.02 | 8.73 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3.11 | -3,446.28 | -4,974.74 | -666.08 |